Compound Radar

Veracyte, Inc. (VCYT) Stock Analysis

Price $50.28
Market cap $4.04B
Next earnings Nov 4, 2026
Entry status Good Entry

Last updated Oct 27, 2026

Published Opportunity Closed

Position closed on Oct 1, 2026 at $44.19 — Technical . Return and QQQ are frozen from the exit date.

Full track record →
Entry $40.57
Return +8.9%
QQQ +3.3%
Alpha vs QQQ +5.6%

Health Check

Last analyzed Oct 23, 2026

82
82/100 Elite Quality
  • Financial Health 85
  • Profitability 95
  • Business Quality 75
  • Balance Sheet 65
  • Cash Flow 80

Why this rating?

Health 82/100 — Elite Quality

Strongest Profitability 95/100
Softest Balance Sheet 65/100
Good Entry

A usable setup — not as clean as Strong Entry, but timing is not mixed or weak.

Company overview

Veracyte, Inc. (VCYT) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates Veracyte, Inc. 82/100 (Elite Quality) due to high business quality, strong revenue growth, and manageable leverage.

Investment profile

  • Quality High
  • Growth Strong
  • Balance Sheet Adequate
  • Valuation Fair

Financial highlights

Valuation

  • P/E 35.66
  • Forward P/E 25.87
  • EV/Revenue 6.1

Profitability

  • Revenue Growth 15.5%
  • Gross Margin 73.8%
  • Operating Margin 15.3%
  • Net Margin 20.4%
  • ROE 8.8%

Financial strength

  • Cash $485.23M
  • Debt $40.11M
  • Net Cash $445.13M
  • Free Cash Flow $126.63M
  • Current Ratio 9.16

Similar companies

Peers in Diagnostics & Research, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Diagnostics & Research →

FAQ

How Compound Radar scores and tracks Veracyte, Inc. (VCYT).

View Methodology & FAQ →